Objectives: To evaluate the association of host genetics with changes in limb or trunk fat in a group of antiretroviral therapy (ART)-naive HIV-infected patients prospectively followed up according to the initiation and the type of ART.
Introduction
Since the introduction of antiretroviral therapy (ART), the life expectancy of patients infected with HIV has increased remarkably. Despite the clinical benefits, multiple metabolic alterations including dyslipidaemia and insulin resistance, which lead to an elevated risk of developing diabetes mellitus and cardiovascular disease, may be present among these patients on ART.
1,2 These complications may be accompanied by an abnormal body fat distribution including peripheral fat loss (arms, legs, face and buttocks), central fat accumulation (dorsocervical area and abdomen) or both. 3 -5 Even though the risk of developing clinically apparent lipodystrophy has decreased as the pattern of drug combinations has evolved, body fat changes are frequently observed after the initiation of ART. 6 Problems with interpreting the pathogenesis of fat changes have led to difficulties in understanding the associated factors. 7 Aside from the cumulative toxicity of the thymidine analogue nucleoside reverse transcriptase inhibitors (NRTIs) (stavudine and, to a lesser extent, zidovudine), 8 environmental factors, age, sex and ethnicity have also been implicated in the development of fat changes. 9, 10 However, body fat changes do not occur in all patients exposed to the same ART and with similar clinical characteristics. Our group and others have already proved the influence of host genetic factors in the development of several metabolic disorders, such as dyslipidaemia and diabetes mellitus, in HIV-infected individuals.
11 -13 Accordingly, specific polymorphisms have been identified to modulate the risk of body fat changes in HIV-infected patients on ART. 14 -16 Nevertheless, the majority of these studies focus on single-gene approaches, and a broad study of host genetic factors involved in body fat changes in HIV-infected patients is lacking. Thus, in order to investigate the hypothesis that body fat changes may be genetically determined through polymorphisms linked to the metabolic syndrome, we aimed to assess the impact of a panel of variants in multiple genes, associated with obesity, insulin resistance, lipid metabolism or lipodystrophy in previously published genetic studies, on changes in limb or trunk fat in a group of HIV-infected ART-naive patients prospectively followed up for 1 year.
Methods

Study design and patients
This was an exploratory pilot study of 89 HIV-infected patients prospectively followed-up at Hospital Clínic de Barcelona (Barcelona, Spain) (n¼59, 66%) and Hospital de la Santa Creu I Sant Pau (Barcelona, Spain) (n¼30, 34%). Participants were recruited between 1 January and 31 December 2003 and the follow-up period ran between 1 January 2004 and 31 December 2006. The study population consisted of randomly selected ART-naive patients who had at least 1 year of follow-up without changes in ART and who did not meet any criteria for AIDS. For the purpose of this study, patients were divided in three groups: those not starting ART (no ART) during the first year of follow-up (n ¼ 24, 27%), patients receiving either zidovudine or stavudine (zidovudine/stavudine) in their first-line regimen (n ¼ 29, 32.6%) and patients receiving neither zidovudine nor stavudine (no zidovudine/stavudine) (n ¼ 36, 40.4%). No lipid-lowering agents or drugs that could have an influence on lipid or fat levels were administered during the study period. As part of the follow-up period, participants underwent dual-energy X-ray absorptiometry (DXA) determinations of total body fat, limb fat and trunk fat at baseline and at Month 12 after exposure to ART. The study was approved by the Institutional Ethics Committee and all participants gave written informed consent for genetic testing.
Body fat assessment
Total body, limb and trunk fat were measured by DXA using Hologic (Bedford, MA, USA) X-ray equipment as previously described. 17 Briefly, patients were positioned straight on the table with all body parts in the scan field, palms down separated from the thighs and legs rotated inward 25 degrees. All the scans were conducted and analysed by the same technician. Fat determinations were expressed in kilograms.
Genetic variants
Fifty single nucleotide polymorphisms (SNPs) in 26 genes, with minor allele frequencies (MAFs) .0.01, were selected for the study. All the tested SNPs had been reported to be significantly associated with obesity, insulin resistance, lipid metabolism or lipodystrophy in previously published studies.
11, 18 -34 In addition, the assessed genes belonged to the diabetes mellitus, inflammation [peroxisome proliferator-activated receptor (PPAR)-signalling] and lipid metabolism pathways according to the Kyoto Encyclopedia of Genes and Genomes. 35 Out of 50 genetic variants, 11% were previously associated with obesity, 12% with insulin resistance, 32% with lipid metabolism and 5% with lipodystrophy (Table 1) . DNA was isolated from whole blood with the QIAcube-QIAamp DNA Blood Mini Kit following the manufacturer's instructions (Qiagen, Venlo, Netherlands).
Genotyping was performed using the Illumina GoldenGate platform (Universitat Autò noma de Barcelona, Barcelona, Spain). Duplicates from 10% of the samples were regenotyped as a genotyping quality control. The resulting genotypes were filtered prior to statistical analysis: 36 Subjects with a genotyping call rate ,80% and SNPs with a genotyping call rate ,95% were excluded from the analysis.
Statistical analysis
Data were analysed longitudinally by modelling the individual effects of the different covariates on limb fat loss or trunk fat gain at Month 12 relative to baseline. Baseline levels of the time-dependent covariates included were age, CD4+ T cell count, HIV viral load, glucose levels, insulin levels, triglyceride levels, total cholesterol levels, high-density lipoprotein (HDL) cholesterol levels and low-density lipoprotein (LDL) cholesterol levels. Fixed covariates included were sex, coinfection with hepatitis C virus (HCV) and/or hepatitis B virus (HBV), the first-line ART regimen and the genetic factors assessed. Medians were used to show central tendencies, and IQRs [¼upper quartile (Q3)2lower quartile (Q1)] were calculated as measures of variability and statistical dispersion.
The study population was initially checked for Hardy-Weinberg equilibrium at all the tested SNPs. Software SPSS v.22 (SPSS Inc., Chicago, IL, USA) was used for all association and statistical analyses. For the purpose of the study, patients were treated as cases if they experienced a decrease in limb fat or an increase in trunk fat at Month 12 relative to baseline. Univariate analyses of all assessed SNPs and non-genetic covariates were performed using logistic regression. Those covariates with a P value ,0.1 in the univariate analysis were considered as candidate predictors for the multivariate model. Candidate SNPs were then evaluated in a multivariate model adjusted for all genetic and non-genetic variables by backward elimination subset selection, with a significance level for entering the effect of ,0.1 and a significance level for removing the effect of 0.05, in order to assess the impact of the genetic variants and the non-genetic covariates on changes in limb or trunk fat. The effect of each variable was assessed using the OR and the variance components calculated in the multivariate model. Statistical significance was defined as a bilateral P value ,0.05. Multiple testing correction for single-point values was performed using Bonferroni correction, 37 yielding a significance level of 0.001 (0.05/number of tests performed). Finally, in order to assess how well the logistic models fitted the observations, the goodness of fit was evaluated by the Negelkerke's pseudo R 2 and Hosmer-Lemeshow tests. 38 
Results
Genotyping
Genotyping results were filtered prior to statistical analysis. Out of 50 SNPs, four (8%) had a genotyping call rate ,95% (rs3846662 and rs3846663 in HMGCR, rs34221221 in FOXC2 and rs131759 in CPT1B). Ultimately, 46 SNPs in 26 genes were included in this study, which consisted of 89 patients. MAF values at all SNPs were similar to the ones previously described for ethnically equal populations. All the tested SNPs were in Hardy -Weinberg equilibrium (P .0.001).
Characteristics of the participants
The baseline characteristics of the study participants are shown in Table 2 . All the participants were Caucasian. The baseline characteristics were [median (IQR)] age 37 (11) years, CD4+ T cell count 228 (271) cells/mm Egañ a-Gorroño et al.
HDL cholesterol 39 (14) mg/dL, triglycerides 104.5 (69.5) mg/dL, total body fat 12.6 (9.6) kg, limb fat 5.6 (4.2) kg and trunk fat, 7.0 (5.5) kg. In addition, 73% of the participants were men and 17% were coinfected with HCV/HBV. Out of 89 patients, 24 (27%) did not start ART during the first year of follow-up, 29 (32.6%) received either a zidovudine-or stavudine-containing first-line regimen and 36 (40.4%) received neither zidovudine nor stavudine. No statistically significant differences were observed between the three groups except for the baseline CD4+ T cell count, which was significantly higher in the no-ART group compared with the zidovudine/stavudine group (P,0.001) and the no-zidovudine/stavudine group (P,0.001).
Effect of antiretroviral regimen on fat changes
Limb fat tended to decrease in the three study groups. However, limb fat loss at Month 12 relative to baseline was statistically significant only in the no-ART group (P, 0.001). Limb fat loss was significantly higher in the no-ART group compared with the zidovudine/stavudine group (P,0.05) and the no-zidovudine/ stavudine group (P,0.01 (Table 3) . Trunk fat tended to increase in the three study groups, although significant differences were not observed in any of the groups. Moreover, no differences were observed between the three groups in terms of increase in trunk fat. At 1 year of follow-up, 61.9%, 66.7% and 67.7% of the patients from the no-ART group, the zidovudine/stavudine group (P ¼ 0.739) and the no-zidovudine/stavudine group (P ¼ 0.664), respectively, experienced a trunk fat gain and no significant differences were observed between groups (Table 3) .
Contribution of SNPs to fat changes
Limb fat loss
After logistic regression-based univariate analyses, six SNPs reached the significance threshold (P, 0.1) for inclusion in the multivariate model (Table S1 , available as Supplementary data at JAC Online): rs1137101 in LEPR, rs1801278 in IRS1, rs3135506 in APOA5, rs2418736 in NFATC3, rs3219177 in RETN and rs266729 in ADIPOQ. From all these variants, only SNP rs1801278 in IRS1 [P ¼ 0.029; OR ¼ 0.13 (0.021 -0.812)] remained significant in the (Table 4) .
Trunk fat gain
After logistic regression-based univariate analyses, five SNPs reached the significance threshold (P, 0.1) for inclusion in the multivariate model (Table S1) 58.5% of the carriers of the minor allele versus 82.6% of the carriers of the common allele experienced trunk fat gain (Table 4) .
Contribution of non-genetic variables to fat changes
Only covariates that reached the significance threshold (P, 0.1) after logistic regression-based univariate analyses were considered as candidates for inclusion in the final multivariate model (Table S2, Statistically significant associations are shown in bold; L95/U95, lower and upper 95% CIs.
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Validation of the models
Hosmer -Lemeshow tests for limb fat loss and trunk fat gain reached a P value of 0.52 and 0.13, respectively, and determined that multivariate models are well-fitting models since we failed to reject the null hypothesis that there is no difference between observed and model-predicted values. Moreover, Negelkerke's measures determined that the models explained 49% of the variability in limb fat loss and 42% in trunk fat gain.
Discussion
The additional contribution of host genetics to the body fat changes associated with HIV and ART remains unclear. This study evaluated the influence of a number of SNPs in multiple genes, consistently associated with obesity, insulin resistance, lipid metabolism and lipodystrophy, on limb or trunk fat changes as measured by DXA. Our results show host genetic variants significantly associated with body fat changes in HIV-infected patients regardless of ART. Thymidine NRTIs, particularly zidovudine and stavudine, have been linked to morphological changes, particularly extremity fat loss. 3, 8, 39 Therefore, ART-naive patients were stratified according to their first-line therapy: not starting ART, having either zidovudine or stavudine or having neither zidovudine nor stavudine in their initial therapy. A decrease in limb fat and an increase in trunk fat were the fat change trends observed irrespective of ART. Although no differences were observed for trunk fat changes, treatment stratification showed a higher limb fat loss in the group of patients who did not start ART in the first year of follow-up relative to the zidovudine/stavudine and no-zidovudine/stavudine groups. This observation suggests that uncontrolled HIV infection has a direct impact on limb fat loss, in agreement with previous reports. 40, 41 However, first-line ART was not identified as a significant variable in the multivariate model for changes in limb fat.
Our study aimed to identify new possible candidate SNPs and reproduce previously reported genetic associations with changes in limb or trunk fat in HIV-infected individuals. With respect to limb fat changes, out of six significant SNPs in the univariate analysis, only rs1801278 in IRS1 remained significant in the final multivariate model, showing a protective role against loss of limb fat. Carriers of this variant tend to lose less weight compared with the non-carriers 21 and have been identified to have a 25% increased risk of developing type 2 diabetes mellitus. 42 In relation to trunk fat gain, out of five significant SNPs in the univariate analysis, rs2228671 in LDLR and rs405509 in APOE remained significant in the final multivariate model, presenting a protective role against gain of trunk fat. Both SNPs are associated with coronary artery disease through a disruption of lipid metabolism, in particular LDL cholesterol. 43, 44 Although cholesterol levels did not associate with fat changes in the study population, our results would corroborate the link between lipid metabolism, cardiovascular risk and lipodystrophy as part of the metabolic syndrome at a genetic level. 45, 46 Overall, our results showed differential polymorphisms to be associated with limb fat loss and trunk fat gain, suggesting that independent molecular pathways are involved underneath these mechanisms. Regarding previously described genetic associations with lipodystrophy, rs3219177 in RETN and rs12691 in CEBP/A maintained statistical associations with fat changes in our study when the univariate analysis was performed. These polymorphisms had been reported to be involved in metabolic complications and fat accumulation in HIV-infected individuals with lipodystrophy. 29, 31 However, these SNPs did not remain significant in the multivariate model and the results could not be reproduced in this study. This fact may rely on the subjective definition of the final phenotype assessed.
Because HIV-associated lipodystrophy has been described to be a multifactorial syndrome, non-genetic factors were also considered in order to explain the interindividual variation in fat changes. Baseline viral load associated with both limb fat loss and trunk fat gain. Our data substantiate previous studies that report a higher baseline viral load to predict a greater loss of limb and trunk fat. 40, 41 Accordingly, several studies report that the severity of HIV infection is associated with an increased SNPs influencing fat changes in HIV patients 3081 JAC prevalence of lipodystrophy, probably as a consequence of persistent HIV-infected macrophages that are modified into a more pro-inflammatory phenotype in adipose tissue. 3, 47, 48 Consistent with this finding, we demonstrated a higher fat loss in non-treated individuals. Our results showed an association of higher fasting glucose levels with a lower loss of limb fat. In the general population, a greater amount of trunk fat has been associated with higher glucose levels, while an accumulation of fat in the legs associates with lower glucose levels. 49 In HIV-infected patients, lipoatrophy has been identified as an independent risk factor for diabetes 50 and thymidine NRTIs have been associated with both insulin resistance and lipoatrophy. 51, 52 With respect to gain of trunk fat, a higher baseline CD4+ T cell count associated with a greater gain of trunk fat, as previously observed in a longitudinal study of the predictors of alterations in body composition. 40 The strengths of this work in the field of HIV are its longitudinal design, the prospective follow-up according to the initiation and type of ARTand the assessment of a panel SNPs in a broad number of genes. However, the present study has certain limitations. First, none of the three associated SNPs remained statistically significant after correction for multiple testing. Nevertheless, current protocols for the multiple correction of candidate SNP association studies in which independent analyses are performed for each marker are conservative and overly stringent. 53 Second, although our models explain around 50% of the variability in limb fat loss and trunk fat gain at Month 12 of follow-up, other genetic and clinical factors that have not been taken into account might be influencing the phenotypes assessed. Third, a limited number of patients was included due to constraints in the availability of DXA. Finally, DXA fat measurements do not distinguish between subcutaneous and intra-abdominal fat, and potential changes in the intra-abdominal compartment were not captured.
In summary, our results suggest that a decrease in limb fat and an increase in trunk fat are the patterns of fat change seen in ART-naive patients regardless of the initiation and type of ART. Moreover, not starting ART led to more pronounced changes in limb fat at Month 12 than did being treated, irrespective of thymidine NRTI use. We demonstrate a statistical association of specific polymorphisms in IRS1, LDLR and APOE as independent favourable markers of fat changes. Furthermore, the influence of non-genetic variables on changes in limb or trunk fat was confirmed. The findings observed in this exploratory pilot study deserve validation in other cohorts with a larger number of patients, and functional studies are necessary to validate those already confirmed associations.
